Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial
Por:
Butler, J, Khan, MS, Friede, T, Placzek, M, Greenberg, B, Coats, AJS, Rosano, G, Abraham, WT, Anker, M, Diek, M, Genis, AB, Filippatos, G, Metra, M, Ninios, V, Spargias, K, Hasenfuss, G, Ponikowski, P, von Bardeleben, RS and Anker, SD
Publicada:
14 may 2026
Ahead of Print:
1 dic 2025
Resumen:
Background and Aims: Mitral transcatheter edge-to-edge repair (M-TEER) using the MitraClip device improves clinical outcomes in patients with moderate-to-severe ventricular secondary mitral regurgitation (vSMR) and heart failure (HF). This study evaluated whether the effects of M-TEER on clinical outcomes vary by baseline health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), and assessed the impact of M-TEER on health status post-randomization. Methods: The RESHAPE-HF2 trial included patients with symptomatic HF and moderate-to-severe vSMR (mean effective regurgitant orifice area .25 cm(2); 14% >.40 cm(2), 23% <.20 cm(2)). The impact of baseline KCCQ-clinical summary score (CSS) on the effect of M-TEER on clinical outcomes was assessed using Cox proportional hazards models. Changes post-randomization in health status and responder analyses were performed to assess the odds ratio (OR) of improvement and deterioration in KCCQ scores. Results: Among 505 patients, M-TEER reduced cardiovascular death or HF hospitalization risk [hazard ratio (HR): .71 (.48-1.05), .50 (.29-.85), and .73 (.38-1.41)] across KCCQ-CSS tertiles of <38.9, 38.9-66.1, and >66.1, respectively (P-trend = .53). Similar results were seen for total HF hospitalization (P-trend = .48). M-TEER improved KCCQ-CSS, total symptom score, and overall summary score at 1, 6, 12, and 24 months compared to medical therapy alone (P < .05 at all time points). More patients in the M-TEER arm experienced a >= 5-point [OR 3.38 (2.09-5.45)], >= 10-point [OR 3.12 (1.93-5.02)], and >= 15-point [OR 3.25 (1.94-5.45)] improvement, and less patients had a >= 5-point deterioration [OR .34 (.19-.57)] in KCCQ-CSS at 6 months. Similar results were seen across other KCCQ domains and all time points. Conclusions: In patients with HF and moderate-to-severe vSMR, M-TEER showed a consistent trend towards a lower risk of HF hospitalization, with or without cardiovascular death, across all KCCQ-CSS tertiles and improved health status over time.
Filiaciones:
Butler, J:
Univ Mississippi, Med Ctr, Dept Med, 2500 N State St, Jackson, MS 39216 USA
Baylor Scott & White Res Inst, 3434 Live Oak St, Dallas, TX 75204 USA
Khan, MS:
Baylor Scott & White Res Inst, 3434 Live Oak St, Dallas, TX 75204 USA
Baylor Coll Med, Temple, TX USA
Baylor Scott & White Hlth Heart Hosp Plano, Plano, TX USA
Friede, T:
Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
German Ctr Cardiovasc Res DZHK, Partner Site Lower Saxony, Gottingen, Germany
Placzek, M:
Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
German Ctr Cardiovasc Res DZHK, Partner Site Lower Saxony, Gottingen, Germany
Greenberg, B:
Univ Calif San Diego, San Diego, CA USA
Coats, AJS:
Univ Warwick, Coventry, England
Rosano, G:
San Raffaele Open Univ Rome, Rome, Italy
San Raffaele Cassino Hosp, Cardiol, Cassino, Italy
Abraham, WT:
Ohio State Univ, Div Cardiovasc Med, Columbus, OH USA
Anker, M:
Charite Univ Med Berlin, Berlin, Germany
Free Univ Berlin, Berlin, Germany
Humboldt Univ, Berlin, Germany
German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany
Berlin Inst Hlth, Ctr Regenerat Therapies, Berlin, Germany
German Heart Ctr Charite, Dept Cardiol Angiol & Intens Care Med CBF, Berlin, Germany
Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
Diek, M:
Charite, Inst Hlth,Ctr Regenerat Therapies BCRT, Dept Cardiol CVK,German Heart Ctr Charite, German Ctr Cardiovasc Res DZHK,Partner Site Berlin, Berlin, Germany
Georg August Univ Gottingen, Univ Med Ctr Gottingen, Dept Cardiol & Pneumol, Gottingen, Germany
:
Hosp Univ Germans Trias i Pujol, Heart Inst, Barcelona, Spain
Filippatos, G:
Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Sch Med, Dept Cardiol, Athens, Greece
Metra, M:
Univ Brescia, Inst Cardiol, ASST Spedali Civili, Brescia, Italy
Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlth, Brescia, Italy
Ninios, V:
European Interbalkan Med Ctr, Thessaloniki, Greece
Spargias, K:
Hygeia Hosp, Dept Transcatheter Heart Valves, Athens, Greece
Hasenfuss, G:
German Ctr Cardiovasc Res DZHK, Partner Site Gottingen, Gottingen, Germany
Ponikowski, P:
Med Univ Wroclaw, Inst Heart Dis, Wroclaw, Poland
Univ Hosp Wroclaw, Wroclaw, Poland
Anker, SD:
Charite, Inst Hlth,Ctr Regenerat Therapies BCRT, Dept Cardiol CVK,German Heart Ctr Charite, German Ctr Cardiovasc Res DZHK,Partner Site Berlin, Berlin, Germany
Georg August Univ Gottingen, Univ Med Ctr Gottingen, Dept Cardiol & Pneumol, Gottingen, Germany
German Ctr Cardiovasc Res DZHK, Partner Site Gottingen, Gottingen, Germany
Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Cardiol, Mainz, Germany
Green Submitted
|